• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

There is a low risk of chronic kidney disease progression following acute kidney injury

byDavid XiangandKiera Liblik
July 25, 2023
in Chronic Disease, Nephrology
Reading Time: 2 mins read
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Share on FacebookShare on Twitter

1. In this prospective cohort study, there was a limited association between acute kidney injury (AKI) and worsening kidney function in patients with chronic kidney disease (CKD).

2. There was no significant decrease in estimated glomerular filtration rate (eGFR) after a mild to moderate AKI in patients with CKD. 

Evidence Rating Level: 1 (Excellent)

Study Rundown: AKI is typically considered a significant risk factor for the progression of loss of kidney function. However, in prior studies that examined this association, there were many methodological limitations. These include not controlling for differences between patients who had an AKI and those patients who did not. Therefore, there is a gap in knowledge as to understanding the true independent association between AKI and changes in kidney function, especially in patients with CKD. Overall, this study found that the independent association between mild to moderate AKI and worsening progressive kidney function is small and has limited clinical significance. This study was limited by participants being research volunteers and thus not generalizable to other populations. Nevertheless, these study’s findings are significant, as they demonstrate that the independent association between mild/moderate AKI and progressive worsening of kidney function in CKD patients is not as significant as previously thought.

Click to read the study in AIM

Relevant Reading: Atypical Antipsychotic Drugs and the Risk for Acute Kidney Injury and Other Adverse Outcomes in Older Adults

RELATED REPORTS

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

2 Minute Medicine Rewind September 7, 2026

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

In-Depth [prospective cohort study]: This multicenter prospective cohort study evaluated patients with CKD in the United States. Patients who were alive, did not withdraw from the study, and did not develop end-stage renal disease by July 1st, 2013 were eligible for the study. Patients who did not fit these criteria were excluded from the study. The primary outcome measured was eGFR. Secondary outcome measures were the change in absolute eGFR value as well as the change in eGFR slope before and after an episode of AKI that the patient was hospitalized for. Outcomes in the primary analysis were assessed via a linear mixed-effects regression model. Based on the primary analysis, most of the AKI episodes were of mild to moderate severity. Additionally, they observed decreases in eGFRcr (-2.30; 95% Confidence Interval [CI], -3.70 to -0.86 mL/min/1.73 m2) and eGFRcys (-3.61; 95% CI, -6.39 to -0.82 mL/min/1.73 m2) after an episode of AKI. However, after adjusting for covariates in the fully adjusted models, the decreases were adjusted to -0.38 (95% CI, -1.35 to 0.59) mL/min/1.73 m2 for eGFRcr and -0.15 (95% CI, -2.16 to 1.86) mL/min/1.73 m2 for eGFRcys. In summary, this study demonstrates that subsequent worsening of kidney function in patients with CKD was small or negligible after accounting for covariates after an episode of mild to moderate AKI.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute kidney injurychronic diseasechronic kidney diseaseinternal medicinenephrologyrenal disease
Previous Post

#VisualAbstract: Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

Next Post

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

RelatedReports

Nephrology

Apixaban (Eliquis) is associated with reduced rates of ischemic stroke and bleeding in patients with atrial fibrillation and advanced chronic kidney disease compared with warfarin (Coumadin)

September 9, 2026
Long-term outcomes for off-pump and on-pump CABG are similar
Weekly Rewinds

2 Minute Medicine Rewind September 7, 2026

September 7, 2026
Blood type correlates with egg reserve in infertile women
Nephrology

Perioperative vitamin C supplementation may not reduce bleeding in percutaneous renal biopsy patients

July 10, 2026
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Chronic Disease

An intradialytic exercise intervention did not improve dialysis adequacy

May 18, 2026
Next Post

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

Factors contributing to parents providing alcohol sips to adolescents

History of delirium tremens associated with greater mortality and morbidity risk than alcohol dependence alone

#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease

#VisualAbstract: Trial of Solanezumab in Preclinical Alzheimer’s Disease

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Gepotidacin (Blujepa) is safe and effective in women with uncomplicated urinary tract infections
  • Most routine blood tests do not require prolonged fasting
  • Pairing cardiac magnetic resonance with electrocardiograms (ECGs) improved artificial intelligence (AI) assessments of cardiovascular diseases
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.